Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cullinan Therapeutics, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
11
4 of them in 2025
Names they are printed under
8
a subsidiary, a former name, its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Cullinan Mica Corporation a subsidiary
named as the applicant on its applications, in US
5 publishedCullinan Oncology, Inc. a former name
named as the applicant on its applications, in US
3 publishedCULLINAN AMBER CORP. a subsidiary
named as the applicant on its applications, in US
1 publishedCullinan Management, Inc. a former name
US, as the owner printed on each patent
0 publishedCullinan Management, Inc. a former name
named as the applicant on its applications, in US
1 publishedCullinan Mica Corporation a subsidiary
US, as the owner printed on each patent
0 publishedCullinan Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 publishedCullinan Therapeutics, Inc. its own name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 30, 2025 | 12,428,480 | Anti-CD19 antibodies and multi-specific binding proteins | Pharmaceuticals | Cullinan Therapeutics, Inc. |
| Sep 2, 2025 | 12,404,328 | Multi-specific binding proteins and methods of use thereof | Biotechnology | Cullinan Management, Inc. |
| Aug 20, 2024 | 12,065,493 | Anti-MICA/B antibodies that block MICA/B shedding and methods of use | Pharmaceuticals | Cullinan Mica Corporation |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 6, 2025 | 2025/0340651 | ANTI-MICA/B ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION AND METHODS OF USE | Pharmaceuticals | Cullinan Mica Corporation |
| Jun 5, 2025 | 2025/0179181 | MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF | Biotechnology | Cullinan Therapeutics, Inc. |
| May 1, 2025 | 2025/0136589 | HETEROBIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS | Organic fine chemistry | Cullinan Oncology, Inc. |
| Jan 30, 2025 | 2025/0034262 | ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USE | Pharmaceuticals | Cullinan Mica Corporation |
| Mar 28, 2024 | 2024/0101630 | BI-FUNCTIONAL LINEAR FUSION COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF | Biotechnology | CULLINAN AMBER CORP. |
| Feb 29, 2024 | 2024/0067731 | MICA/B ANTIBODIES AND METHODS OF USE | Pharmaceuticals | Cullinan Mica Corporation |
| Feb 9, 2023 | 2023/0037815 | ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS | Pharmaceuticals | Cullinan Oncology, Inc. · patent 12,428,480 granted from it |
| Feb 2, 2023 | 2023/0032087 | ANTI-SERUM ALBUMIN ANTIBODIES | Biotechnology | Cullinan Oncology, Inc. |
| Aug 19, 2021 | 2021/0253711 | ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USE | Pharmaceuticals | Cullinan Mica Corporation · patent 12,065,493 granted from it |
| Aug 5, 2021 | 2021/0238286 | MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF | Biotechnology | Cullinan Management, Inc. · patent 12,404,328 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Biotechnology 2 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.